Novartis considers granting managed access to investigational or pre-approval products via single patient access provided the Managed Access criteria are fulfilled.
|
Product |
Indication |
|
Capmatinib |
MET dysregulated Non-Small Cell Lung Cancer (NSCLC) |
|
Ceritinib |
Non-small cell lung cancer: ALK positive tumors, previously pre-treated with ALK inhibitors or naive |
|
Clofazimine |
Mycobacterial infection |
|
Iptacopan |
C3 Glomerulopathy (C3G) |
|
Tisagenlecleucel |
Acute lymphoblastic leukaemia; Diffuse large B-cell lymphoma refractory |
COVID-19 Information Center https://www.novartis.com/coronavirus
Novartis announces plan to initiate clinical study of Jakavi® in severe COVID-19 patients and establish international compassionate use program - Novartis to establish compassionate use program for COVID-19 patient access and undertake steps to ensure uninterrupted supply of Jakavi for currently licensed indications. (Jakavi/Jakafi is marketed by Novartis outside the United States. In the United States, the product is marketed by Incyte, Inc.)
The multiple sclerosis drug Gilenya and fever drug Ilaris are also being studied for their effect on complications related to COVID-19.
Novartis donates 20,000 doses of hydroxychloroquine for COVID-19 PEP clinical trial. For more information:
https://newsroom.uw.edu/news/does-antimalarial-drug-prevent-covid-19-study-seeks-answers
https://depts.washington.edu/covid19pep/
Novartis donation: Consignment of 30 million hydroxychloroquine tablets ships to US Department of Health and Human Services